...
首页> 外文期刊>Expert review of respiratory medicine >Advances in bronchopulmonary dysplasia
【24h】

Advances in bronchopulmonary dysplasia

机译:支气管肺发育不良的研究进展

获取原文
获取原文并翻译 | 示例

摘要

Bronchopulmonary dysplasia (BPD) is a chronic respiratory condition primarily affecting infants born less than 28 weeks gestational age. BPD and the diagnostic criteria that define it have evolved since the initial description of the disease more than four decades ago. BPD is one of the most common and serious complications of extreme premature birth. Despite advances in neonatal care and continued research into therapeutic strategies the incidence of BPD remains unchanged. Pharmacologic approaches to the management of BPD include methylxanthines, corticosteroids, and vitamin A supplementation. Supportive therapies including the increased use of non-invasive ventilation and careful oxygen delivery strive to reduce injury inflicted on the developing lung. Stem cell-based therapies are a new investigational strategy showing promise for the prevention or treatment of BPD. The goal of this review is to highlight the evolution of BPD and review current and potential future therapeutic strategies for BPD.
机译:支气管肺发育不良(BPD)是一种慢性呼吸系统疾病,主要影响胎龄小于28周的婴儿。自从四十多年前对该疾病进行初步描述以来,BPD及其定义的诊断标准就已经发展起来。 BPD是极端早产的最常见和最严重的并发症之一。尽管新生儿护理取得了进步,并且对治疗策略进行了持续的研究,但BPD的发生率仍保持不变。 BPD的药理方法包括甲基黄嘌呤,皮质类固醇和维生素A补充剂。支持疗法包括增加无创通气的使用和谨慎的氧气输送,努力减少对发展中的肺部造成的伤害。基于干细胞的疗法是一种新的研究策略,显示出有望预防或治疗BPD。这篇综述的目的是强调BPD的发展,并回顾BPD的当前和潜在的未来治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号